Last reviewed · How we verify

NCT07053930

Comparison of the Mean Duration of 3rd Stage of Labour Between Intraumbilical and Intravenous Oxytocin

Completed NA Last updated 8 July 2025
What this trial tests

NA trial testing Intraumbilical oxytocin in Labor in 100 participants. Completed in 31 March 2025.

Timeline
1 October 2024
Primary endpoint
31 March 2025
31 March 2025

Quick facts

Lead sponsorRESnTEC, Institute of Research
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 October 2024
Primary completion31 March 2025
Estimated completion31 March 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

RESnTEC, Institute of Research

Who can join

Adults 18 to 40, female only, with Labor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is always a debate for choosing the best method for management of the third stage of labour (TSL) in the general practice for reducing the duration of TSL. Although intravenous oxytocin is more extensively used in general practice for managing TSL than intraumbilical, it still needs to be properly investigated among local populations and in local settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Labor

Currently open trials in the same condition.

Other RESnTEC, Institute of Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07053930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing